Literature DB >> 24853452

Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation.

Jonathan Lai1, Santiago Garcia-Tizon Larroca, Gergana Peeva, Leona C Poon, David Wright, Kypros H Nicolaides.   

Abstract

OBJECTIVE: To assess the risk for preeclampsia (PE) by maternal characteristics, serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) at 30-33 weeks' gestation.
METHODS: This was a screening study in singleton pregnancies including 2,140 that subsequently developed PE and 83,615 that were unaffected by PE, gestational hypertension or delivery of small-for-gestational-age neonates (normal group). We developed a survival time model for the time of delivery for PE by combination of maternal characteristics and history with PlGF and sFlt-1 multiple of the median (MoM) values (biochemical test). Data on third-trimester PlGF and sFlt-1 were available in 118 cases of PE and 3,734 of normal group. The detection rate (DR) of PE requiring delivery within 4, 6 and 8 weeks of the visit was estimated.
RESULTS: In pregnancies with PE, the log10 MoM values of PlGF and sFlt-1 were linearly related to gestational age at delivery. Screening by the biochemical test detected 100, 76, and 62% of PE with delivery within 4, 6 and 8 weeks of the visit, at a fixed false-positive rate of 5%.
INTERPRETATION: Testing by PlGF and sFlt-1 at 30-33 weeks could identify all pregnancies developing PE and requiring delivery within the subsequent 4 weeks.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24853452     DOI: 10.1159/000359968

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  11 in total

Review 1.  Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity.

Authors:  Roberto Romero; Offer Erez; Maik Hüttemann; Eli Maymon; Bogdan Panaitescu; Agustin Conde-Agudelo; Percy Pacora; Bo Hyun Yoon; Lawrence I Grossman
Journal:  Am J Obstet Gynecol       Date:  2017-06-12       Impact factor: 8.661

2.  Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants.

Authors:  Alexander Ep Heazell; Dexter Jl Hayes; Melissa Whitworth; Yemisi Takwoingi; Susan E Bayliss; Clare Davenport
Journal:  Cochrane Database Syst Rev       Date:  2019-05-14

3.  Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia.

Authors:  Glenn E Palomaki; James E Haddow; Hamish R M Haddow; Saira Salahuddin; Carl Geahchan; Ana Sofia Cerdeira; Stefan Verlohren; Frank H Perschel; Gary Horowitz; Ravi Thadhani; S Ananth Karumanchi; Sarosh Rana
Journal:  Prenat Diagn       Date:  2015-02-04       Impact factor: 3.050

Review 4.  Early prediction of preeclampsia.

Authors:  Leona C Poon; Kypros H Nicolaides
Journal:  Obstet Gynecol Int       Date:  2014-07-17

Review 5.  Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice.

Authors:  H Stepan; I Herraiz; D Schlembach; S Verlohren; S Brennecke; F Chantraine; E Klein; O Lapaire; E Llurba; A Ramoni; M Vatish; D Wertaschnigg; A Galindo
Journal:  Ultrasound Obstet Gynecol       Date:  2015-03       Impact factor: 7.299

Review 6.  A Dormant Microbial Component in the Development of Preeclampsia.

Authors:  Douglas B Kell; Louise C Kenny
Journal:  Front Med (Lausanne)       Date:  2016-11-29

7.  External validation of prognostic models predicting pre-eclampsia: individual participant data meta-analysis.

Authors:  Kym I E Snell; John Allotey; Melanie Smuk; Richard Hooper; Claire Chan; Asif Ahmed; Lucy C Chappell; Peter Von Dadelszen; Marcus Green; Louise Kenny; Asma Khalil; Khalid S Khan; Ben W Mol; Jenny Myers; Lucilla Poston; Basky Thilaganathan; Anne C Staff; Gordon C S Smith; Wessel Ganzevoort; Hannele Laivuori; Anthony O Odibo; Javier Arenas Ramírez; John Kingdom; George Daskalakis; Diane Farrar; Ahmet A Baschat; Paul T Seed; Federico Prefumo; Fabricio da Silva Costa; Henk Groen; Francois Audibert; Jacques Masse; Ragnhild B Skråstad; Kjell Å Salvesen; Camilla Haavaldsen; Chie Nagata; Alice R Rumbold; Seppo Heinonen; Lisa M Askie; Luc J M Smits; Christina A Vinter; Per Magnus; Kajantie Eero; Pia M Villa; Anne K Jenum; Louise B Andersen; Jane E Norman; Akihide Ohkuchi; Anne Eskild; Sohinee Bhattacharya; Fionnuala M McAuliffe; Alberto Galindo; Ignacio Herraiz; Lionel Carbillon; Kerstin Klipstein-Grobusch; Seon Ae Yeo; Joyce L Browne; Karel G M Moons; Richard D Riley; Shakila Thangaratinam
Journal:  BMC Med       Date:  2020-11-02       Impact factor: 8.775

Review 8.  Angiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical Integration.

Authors:  Ignacio Herraiz; Elisa Simón; Paula Isabel Gómez-Arriaga; José Manuel Martínez-Moratalla; Antonio García-Burguillo; Elena Ana López Jiménez; Alberto Galindo
Journal:  Int J Mol Sci       Date:  2015-08-13       Impact factor: 5.923

9.  Serum biomarkers combined with uterine artery Doppler in prediction of preeclampsia.

Authors:  Lijie Li; Yanmei Zheng; Ying Zhu; Jianchun Li
Journal:  Exp Ther Med       Date:  2016-08-29       Impact factor: 2.447

10.  A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.

Authors:  H Stepan; M Hund; M Gencay; B Denk; C Dinkel; W E Kaminski; P Wieloch; B Semus; T Meloth; L-A Dröge; S Verlohren
Journal:  Hypertens Pregnancy       Date:  2016-03-30       Impact factor: 2.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.